POET Technologies ($POET): Blazar nominated at ECOC 2026

01 The second quarter 2026 print, reported August 13, 2026

POET filed its interim statements and management discussion on August 13, 2026, one day before the regulatory deadline. The documents reached SEDAR+ and were furnished to the SEC on a Form 6-K accepted at 09:13:55 Eastern time, with a results press release issued at 07:01 Eastern. Revenue for the quarter was $569,925, against $503,389 in the first quarter of 2026 and $268,469 in the second quarter of 2025: up 13% sequentially and 112% year on year, which the company describes as its sixth consecutive quarter of sequential growth. The net loss was $11,338,060, or $0.07 per share, narrowing from $12,344,086 and $0.08 in the first quarter and from $17,263,375 and $0.21 a year earlier.

Two lines inside that table carry more weight than the loss itself. Finance advisory fees of $6,172,500 are the largest single cost of the quarter, larger than research and development, and they are the price of the May financing: the offering was non-brokered, which does not mean it was free. Other income of $4,299,496 is almost entirely interest, and it is now running at a level that covers a meaningful share of the cash operating cost: the treasury has become a profit centre in its own right while the product is still pre-revenue at scale.

The derivative liability adjustment of $5,531,784 is a non-cash gain and does not reflect operations. It is the quarterly remeasurement of warrants that are exercisable into a variable number of shares, and the company states the mechanism explicitly in the notes.

The reporting rhythm, now with the second quarter filled in

POET is a reporting issuer in Canada and, because its shares are listed on Nasdaq, it is not a venture issuer under National Instrument 51-102. Non-venture issuers must file an interim financial report within 45 days of the end of the interim period. The pattern is tight against that deadline in every recent quarter.

On that rhythm the third quarter of 2026 ends on September 30 and the interim report is due by November 14, 2026. No date has been announced for it, and the company has not committed to one.

There is no conference call. This is a genuine difference from most Nasdaq-listed peers and it is useful to know in advance rather than searching for a dial-in that does not exist. POET does not host a quarterly earnings call, does not publish a webcast link with its results and does not issue prepared remarks: the August 13 release follows the same pattern as every quarterly release since the second quarter of 2025. Management commentary arrives as quoted paragraphs inside the results press release, and the one live event of the year is the annual general meeting, at which the chief executive gives a business update with a question and answer session. The 2026 edition was held virtually on June 26 and the recording and slides were posted afterwards.

Direct links: the August 13, 2026 Form 6-K · POET filings on EDGAR · SEDAR+ · POET investor relations.

02 Executive summary

Q2 revenue was $569,925 and IFRS net loss $11.338M. Cash plus short-term investments reached $796.342M at June 30 after major equity financing. The $50M Lumilens purchase order remains subject to development, qualification and manufacturing scale-up; the $500M-plus framework is potential business, not booked revenue.

The interposer platform addresses optical assembly cost and scaling. Cash supports development and manufacturing investment, while announced purchase orders provide commercial checkpoints.

Revenue remains small relative to capital raised. Customer qualification, shipment execution, spending and dilution remain central risks. A partnership, trade-show presentation or award nomination does not establish revenue.

SEC · Q2 financial statements · POET · Q2 results

POET Technologies designs optical engines and light sources for artificial intelligence networks and hyperscale data centers, built on a patented platform it calls the POET Optical Interposer. The technology has been validated by partners, by industry awards and by paying customers ordering samples and pre-production volumes. What it has not yet done is produce revenue at any material scale. Cumulative revenue for the three full years 2023, 2024 and 2025 plus the first half of 2026 is $2,655,383. Over the same period the accumulated deficit reached $320,776,480 at June 30, 2026.

Against that, the balance sheet has been transformed. Six equity financings between May 2025 and May 2026 raised $830 million in gross proceeds, a figure the chief executive repeated at the June 2026 annual meeting and the company restated in a July 14, 2026 note on its own website. The largest of them, $400 million, closed on May 18, 2026 with a single institutional buyer, MMCAP International Inc. SPC, at $21.00 per unit, a premium to the prior close, with a three-year warrant struck at $26.25.

The second quarter print of August 13, 2026 put a filed number on both halves of that sentence: $796,341,903 of cash and short-term investments, and $569,925 of quarterly revenue. The company now has more cash than most of its listed peers in optical components and almost no revenue to defend it. That combination is the whole debate. It is also why the two most important sentences in POET’s disclosure record over the last twelve months are not about technology at all. The first is from April 27, 2026: Marvell, having acquired Celestial AI, cancelled every purchase order Celestial had placed with POET, the orders POET had been citing publicly since April 2023. The second is from May 14, 2026: Lumilens placed a $50 million initial purchase order, and the same release states that fulfilment “is subject to the successful development and ultimate qualification of the modules, as well as the successful scaling of manufacturing capability.”

Three categories need to be kept apart when reading anything about this company, because commentary routinely merges them: revenue actually recognized on a filed income statement, purchase orders that are signed but conditional on qualification and manufacturing scale-up, and joint development agreements, collaborations and memoranda that carry no order at all. POET has entries in all three columns. The third column is by far the longest, and it is the one most often described as if it belonged in the first.

03 Market

Finviz retrieved September 20. Float, short interest and ownership have their own reporting dates and lags; these are not real-time observations. Filed share counts are distinct from provider estimates.

Finviz · 20/09 · SEC · MD&A · 13/08

Price, performance, float, ownership, short interest, average volume and the consensus target below are from Finviz, pulled during the session of Thursday, August 13, 2026 at 10:54 Eastern time, the day the second quarter results were released. Intraday values move; the reference time is stated so the reading can be reproduced. Company financial figures come from SEC filings and company releases, each carrying its own reference date.

Finviz reports shares outstanding of 152.89 million, which is the figure from the March 31, 2026 balance sheet and predates the May unit offering. The count used throughout this page is the one on the cover of the June 30, 2026 interim statements, 173,035,169. The market capitalisation shown by the same source, roughly $1.60 billion at $9.27, is consistent with the larger count rather than the smaller one.

Peer comparison, Finviz reading of August 13, 2026 at 10:54 Eastern

The twelve-month range is the context for everything else: an intraday high of $20.81 on May 14, 2026, the day the Lumilens agreement was announced and the day before a $400 million offering was disclosed, against an intraday low of $3.87 on November 21, 2025. A range of more than five to one in twelve months is a statement about how thinly the outcome is currently known. The quarter-to-date performance of -35.49% is measured from inside that May spike, not from a settled level.

Short interest at 28.49% of float is down from 30.11% at the August 7 reading used in the previous version of this page, and remains among the highest in the peer set. Of the eight names in the table, five carry a short float above 28%.

Analyst coverage is reported here in a deliberately narrow form. The consensus target above is a Finviz aggregate of third-party estimates. Individual houses, ratings and note dates were not verified for this update, so no coverage table is presented. A consensus figure without named notes behind it is a market-data point, not research, and it is neither a company figure nor a Merlintrader forecast.

04 Verified developments, most recent first

05 Financial charts

SEC · Q2 financial statements · SEC · MD&A · 13/08

Every bar below is drawn from a figure published by POET in an interim or annual financial statement or in a results press release. Bar widths are the stated value as a percentage of the largest bar in the same chart.

Revenue by quarter, Q1 2025 to Q2 2026 (US dollars)

Source: the five-quarter summary in POET’s second quarter 2026 results release of August 13, 2026, and the eight-quarter table in the accompanying management discussion. The trend is up in every quarter and the scale is the point: the largest bar is $569,925. The company describes this line as non-recurring engineering and product revenue combined, and does not split the two. The 112% year-on-year increase is measured against $268,469.

Total operating costs by quarter, Q1 2025 to Q2 2026 (US dollars)

Calculated by adding the seven cost lines POET publishes in its own quarterly table: research and development, depreciation and amortization, professional fees, wages and benefits, stock-based compensation, general expenses and rent, and finance advisory fees. Cost has more than doubled in five quarters. In the second quarter of 2026 the largest single line is not research and development but finance advisory fees of $6,172,500, the cost of raising the $400 million, against $3,252,500 in the first quarter. Research and development of $5,784,056 is the second line and the one that grew for product reasons, up 84% on the $3,150,044 of a year earlier, which the company attributes to engineering headcount, customer-specific programmes and manufacturing readiness. Stock-based compensation of $3,816,906 is non-cash.

Cash and short-term investments at each reporting date (US dollars)

All four bars are balance sheet figures: cash and cash equivalents plus short-term investments, from the audited 2025 annual statements, the first quarter 2026 statements and the June 30, 2026 interim statements. At June 30 the split is $432,531,904 of cash and cash equivalents and $363,809,999 of short-term investments, the latter held as guaranteed investment certificates with Canadian banks. Within the cash line, $404,211,716 sits in current accounts and $28,320,188 in term deposits and high-interest savings earning between 2.25% and 3.24%.

The filed figure of $796.3 million comes in below the “more than $830 million” the company described at the June annual meeting and repeated on its website on July 14, 2026, and the gap is accounted for rather than unexplained. Between March 31 and June 30 POET received $400,000,020 of gross proceeds, spent $12.2 million on operations in the quarter, lent $30 million to an unnamed borrower at 6%, paid $2,955,150 for a 4.99% stake in Lessengers and incurred the finance advisory fees on the raise. Those uses are disclosed individually in the interim statements.

Common shares issued and outstanding (millions)

Sources: the share capital note in the 2025 annual statements and the first quarter 2026 statements for the first three bars. The May 18, 2026 figure of 172,595,406 is taken from the prospectus supplement filed that day and independently repeated in the Schedule 13G filed by Citadel Securities on July 8, 2026. The company stated 172,590,000 shares at the June 26 annual meeting. The count has risen 126% since the start of 2025.

Gross proceeds by financing round, May 2025 to May 2026 (US dollars)

Sources: the share capital note in the first quarter 2026 financial statements for the first five rounds, and the closing press release of May 18, 2026 for the sixth. The first three were unit placements priced in Canadian dollars with warrants attached; the October 2025 and January 2026 rounds were registered direct offerings of common shares at $7.25; the last was a registered direct offering of shares with a warrant at a combined $21.00. The six rounds sum to $830.0 million, which is the figure management cites.

06 What the POET Optical Interposer actually is

An optical transceiver converts electrical signals into light and back again. Building one has traditionally meant placing lasers, modulators, photodiodes, multiplexers, drivers and amplifiers next to one another and aligning them to fiber one at a time, with a machine holding each part while light is measured through it. That step, called active alignment, is the single largest source of cost, yield loss and throughput limitation in optical module assembly. It is manual, it is slow, and it does not get cheaper with volume in the way semiconductor processing does.

The POET Optical Interposer is a silicon substrate on which those components are assembled at wafer level using chip-scale processes, with the optical waveguides and coupling structures already patterned into the substrate. Because the optical paths are defined lithographically rather than by physically nudging parts into position, assembly can be passive. POET’s own description of the resulting advantage is consistent across filings and releases: lower cost, lower power, smaller size and scalability to high production volumes, with wire bonds eliminated, the multiplexer and demultiplexer monolithically integrated, and a materially reduced bill of materials.

The product families

• POET Infinity is the 800G line. It is built from 400G optical engines that can be daisy-chained, and it is the product behind the October 2025 production order: 2xFR4 and 2xDR4 400G transmit engines and 800G 2xFR4 and DR8 receive engines, with integrated electro-absorption modulated lasers, drivers and multiplexers on the transmit side and high-speed photodiodes, transimpedance amplifiers and demultiplexers on the receive side.
• POET Teralight extends the same platform to 1.6 Tbps, with transmit and receive chipsets sampled during 2025. It won the Product Innovation Award at the 12th ICCSZ Infostone Awards and, according to the company, an elite score of 4.5 in the 2026 Lightwave Innovation Reviews.
• POET Blazar is the hybrid laser at the center of the external light source strategy, with POET Starlight as the external light source product line. At the June 2026 annual meeting management said Blazar remains on schedule for deployment at scale in 2028, which is the furthest-out date the company has publicly attached to a product.

Why co-packaged optics matters here

Today’s artificial intelligence clusters connect switches and accelerators using pluggable transceivers that sit at the faceplate. As bandwidth per port rises from 400G to 800G to 1.6T, the electrical distance between the switch silicon and the faceplate becomes a power and signal-integrity problem. Co-packaged optics moves the optical engine onto the same substrate as the switch or accelerator package, which shortens that electrical path dramatically. It also removes the laser from the hot package, which is why an external light source becomes a separate product category rather than a component inside the module.

POET’s argument is that a platform designed for wafer-level integration is agnostic to which architecture wins, because the same interposer can be built into a pluggable module today and sit beside a switch ASIC tomorrow. The claim that a customer can qualify once and migrate across speed tiers without a ground-up redesign is a real commercial argument in a market where hyperscale qualification cycles can run a year or more. It is also, as of August 2026, a claim that has not yet been demonstrated by a customer taking a POET-based product from qualification through to volume deployment.

07 Partners, collaborations and the Xiamen joint venture

SEC · MD&A · 13/08 · SEC · Q2 financial statements

POET runs what it calls a fab-light strategy: it designs, and partners manufacture. The list of named counterparties is unusually long for a company of this size, and each entry sits at a different point on the spectrum from signed commercial commitment to exploratory development.

08 Orders and revenue

Actual H1 revenue was $1,073,314, comprising non-recurring engineering and products. Cumulative revenue from 2023 through June 2026 was $2,655,383. The $50M Lumilens order, potential $500M-plus five-year relationship and development programmes must not be treated as recognised sales.

Lumilens: initial order announced May 14, 2026, conditional on development, module qualification and manufacturing scale. Engineering samples were targeted for late 2026 and the ramp linked to 2027 deployments. The release does not establish receipt of $50M cash. The $30.142M deferred customer consideration is the accounting value of customer warrants, to be amortised with revenue; it is not a customer cash deposit.

The Q2 release adds a $2.4M purchase order from an existing customer, a development agreement with a Tier 1 laser company and an exclusive Blazar component arrangement. Counterparties are unnamed. The development and supplier arrangements are not additional sales orders. The more-than-$5M Infinity order announced in October 2025 remains a historical reference with H2 shipment targets; full execution has not been verified here.

POET · Q2 results · POET · Lumilens · 14/05 · SEC · Q2 financial statements

POET has issued a large number of announcements naming large companies. Very few of them carry a number, and the ones that do carry conditions. Sorting them properly is the single most useful analytical act a reader can perform on this company, and the April 2026 cancellation is the reason.

What has actually converted into revenue

Revenue recognized on filed income statements since the start of 2023 totals $2,085,458: $465,777 in 2023, $41,427 in 2024, $1,074,865 in 2025 and $503,389 in the first quarter of 2026. All of the 2025 revenue was recorded in the Asia segment. The company describes the line as non-recurring engineering and product revenue combined and does not disclose the split, the number of customers or any customer concentration percentage. The contract liability note shows customer deposits of $230,000 taken in the first quarter of 2026 and $503,389 of revenue recognized in the same period, with an accounts receivable balance of $290,368 at March 31, 2026 against nil at December 31, 2025.

What is signed but conditional

• Lumilens, $50 million. The announcement is explicit: “Fulfilment of the purchase orders and associated revenues is subject to the successful development and ultimate qualification of the modules, as well as the successful scaling of manufacturing capability.” Engineering samples are expected in late 2026. A purchase order that depends on a module that does not yet exist passing a qualification that has not yet started is a commitment to buy something conditional, not a backlog figure.
• The unnamed systems integrator, more than $5 million. Announced October 22, 2025 for shipment in the second half of 2026. The customer is not identified and no update on shipment status has been published since.

What carries no order at all

LITEON, Lessengers, Quantum Computing Inc., Sivers, Semtech and NTT Innovative Devices are development collaborations. Two of them require POET to spend money rather than receive it: the QCi agreement states that POET funds the 400G-per-lane modulator development. Collaborations of this kind are how photonics products get built and their existence is a legitimate signal that credible counterparties take the platform seriously. They are not orders and none of them has a disclosed value.

The aggregate management figure, and how to read it

At the June 2026 annual meeting management said POET has more than ten active customer engagements which combined are expected to exceed $100 million in future annual revenue. That number is a management expectation about engagements, not a contracted backlog, and POET does not publish a backlog figure in the way an aerospace or defense supplier does. It sits alongside a stated target of more than 30,000 optical engine shipments across 2026 and a capacity ambition of up to one million units per month by the end of 2027. All three are forward-looking statements made outside a financial statement.

09 Q2 financials and liquidity

Revenue grew 112.3% year on year and 13.2% sequentially but remains small. The loss includes a $5.532M non-cash warrant remeasurement gain and $4.299M of other income including interest. IFRS R&D expense is $6.993M; the management summary’s $5.784M uses a different cost classification and is not the IFRS line.

Q2 operating cash use was approximately $12.2M. The filed 2026 capital budget is $14.5M, with $5.509M spent in H1. The $44M project plan spans development and corporate activities over multiple periods; it should not simply be added to the capital budget as an immediate obligation. Liquidity is large relative to historical burn but does not ensure investment returns or preclude future financing.

The $30M of loans were advanced across H1, not all in Q2: $10M on January 7, $5M on January 21 and $15M on April 23. The borrower is unnamed; interest is 6%, repayment is due at the earlier of a liquidity event and five years, with conversion rights in specified circumstances. Lessengers is a 4.99% equity investment, distinct from revenue or cash.

SEC · Q2 financial statements · SEC · MD&A · 13/08 · POET · Q2 results

The annual columns come from the audited statements and the selected annual information table, where the line is total operating expenses. The two quarterly columns are the sum of the seven cost lines POET publishes in its own quarterly summary. The two bases are close but not identical.

Two features of this table need explanation. First, the collapse in total liabilities between December 2025 and March 2026, from $144.78 million to $13.13 million, is not a debt repayment. It is the derivative warrant liability falling from $135,631,585 to $2,584,759 because $131,444,528 of warrant fair value was reclassified out of liabilities and into the equity warrant reserve. That reclassification followed the change of functional currency to United States dollars on October 1, 2025, which removed the foreign-currency feature that had forced warrants issued in Canadian dollars to be carried as liabilities and remeasured every quarter. The same mechanism explains the $30.7 million non-cash loss in the fourth quarter of 2025 and the $15.4 million non-cash gain in the first quarter of 2025: both were fair-value swings on that liability, not operating events.

Liabilities then move the other way between March and June, from $13.13 million to $34.30 million, and again the cause is not borrowing. The derivative warrant liability rises from $2,584,759 to $22,020,827 because the 2,292,140 vested Lumilens warrants carry a cashless exercise feature: the number of shares issuable varies with the share price at exercise, which forces them into liabilities at a fair value first recorded at $30,142,069 and remeasured every quarter thereafter.

Second, the only real debt is $5,800,000 of convertible debt carried as a current liability at December 31, 2025, March 31, 2026 and June 30, 2026, reduced from $6,500,000 during 2025 by a $700,000 repayment. It is payable over four years and the holder may convert any unpaid amount at its discretion, which is why it sits in current liabilities. Lease liabilities are $1,997,859 in total. Against $796.3 million of cash and investments, the balance sheet carries effectively no leverage.

Two assets on the June 30 balance sheet are new and neither is operating. A loan receivable of $30,644,384 records three advances of $10 million, $5 million and $15 million made on January 7, January 21 and April 23, 2026 to a borrower the company does not name, for general working capital, at 6% compounding daily and 8% on default, repayable on the earlier of a liquidity event and five years, with a right for POET to convert into equity of the borrower if certain events occur. An investment of $2,955,150 buys 4,500 redeemable convertible preferred shares, 4.99%, of Lessengers Inc., the private company POET is already co-developing a 1.6T module with, carried at fair value through other comprehensive income. A company with no product revenue at scale is now also a lender and a minority shareholder in its own development partner.

Burn and runway

Operating cash outflow was $12.2 million in the second quarter of 2026, against $8.8 million in the first quarter and $7.8 million in the second quarter of 2025. For the six months the filed figure is $21,079,966. Annualising the most recent quarter gives roughly $49 million a year, and the cost base is still rising: research and development is up 84% year on year and wages and benefits for the half year run at more than double the prior-year level, with key management compensation alone at $11,160,359 for the six months against $3,751,045.

Against $796.3 million of cash and short-term investments, an operating burn near $49 million a year is not a financing question in any ordinary sense. The company also earns $4.3 million a quarter of interest and other income, which covers a meaningful share of it. POET’s risk is not that it runs out of money before the technology works. It is that money is not what stands between the technology and revenue.

Where the money is meant to go is now itemised in a filing rather than in a presentation. The management discussion sets out a programme table totalling $44 million: $7.0 million on module development through to production in the third quarter of 2027, $6.5 million on light sources for artificial intelligence, $5.5 million on the 800G and 1.6T transmit programme, $7.0 million on the Malaysia expansion through the third quarter of 2026, and $18.0 million on corporate development across 2026. Separately, POET states an approved capital budget of $14.5 million for 2026 covering research and development, equipment, manufacturing equipment and patent registration, of which $5,508,836 was spent in the first half.

That approved capital budget is the number to hold against the roughly $50 million of capital equipment purchases management described at the June annual meeting for the second half of 2026. The two figures are not stated on the same basis and the company does not reconcile them, so what stands is a filed budget of $14.5 million for the year against a $50 million figure stated at a meeting. Capital expenditure is the hardest evidence a capacity expansion is real, and the third quarter cash flow statement is where the answer will be.

Four things to look for in the next interim report, due by November 14, 2026. One: whether any revenue is recognised against the Lumilens order or the October systems-integrator order, and whether the $30,142,069 of deferred customer consideration begins to amortise, which happens only when product revenue from that customer starts. Two: the new $2.4 million purchase order announced on August 13, and whether it ships. Three: property and equipment additions against the $14.5 million approved budget. Four: whether the loan receivable is repaid, converted or extended, and whether the borrower is ever named.

10 Capital and dilution

Adding common shares, warrants, options and RSUs gives 261,414,953, about 51% above the August 13 common count. This is not a forecast of diluted shares: it includes unvested warrants, excludes variable-price debt conversion and can differ under cashless exercise. The remaining 20,629,268 Lumilens warrant shares depend on payment milestones; exercise is neither immediate nor certain.

The May 18 financing issued 19,047,620 units at $21, each with a share and warrant, for $400,000,020 gross. Q2 added 20,141,565 shares versus March 31; 439,763 is only the increase from the post-offering May count. Q2 finance advisory fees were $6.173M: non-brokered does not mean cost-free.

Remaining Sanan debt is $5.8M, with a $1M payment on October 31, 2026, unless converted. The conversion price is the higher of the preceding 30-day VWAP and prior-day close. This debt arose from acquiring the remaining 24.8% interest on December 31, 2024 for $6.5M, not a 2025 acquisition.

SEC · Q2 financial statements · SEC · MD&A · 13/08 · POET · Lumilens · 14/05

POET has funded itself entirely with equity, and the share count reflects it. From 76,507,157 shares at January 1, 2025 the company reached 132,021,526 at December 31, 2025, 152,893,604 at March 31, 2026, 172,595,406 at May 18, 2026 173,035,169 at June 30, 2026 and 173,058,088 at August 13, 2026: an increase of 126% in eighteen months. That is the cost of the $830 million of gross proceeds. The second quarter itself added only 439,763 shares, almost all from warrant exercises, because the May offering had already closed before the quarter ended. Share capital on the balance sheet stands at $720,134,275 and the warrant reserve at $435,942,629, against an accumulated deficit of $320,776,480.

What is outstanding on top of the shares

The counts stated at August 13, 2026 are 78,734,968 warrants struck between $1.09 and $26.25, 5,369,393 options between $1.27 and $6.33 at a weighted average of $2.10, and 4,252,504 restricted stock units. Adding those to the 173,058,088 shares in issue at the same date gives 261,414,953 on full exercise, 51% above the current count. The warrant table carries a weighted average of $4.39 against the June 30 balance, which cannot be reconciled with tranches of 19,047,620 at $26.25 and 22,921,408 at $8.25: on those two alone the average would have to exceed $9. The tranche-by-tranche figures are used throughout this page in preference to that average. Two qualifications matter. The Lumilens warrant only vests beyond its first tranche if Lumilens actually pays for product, so most of that 22.9 million is a dilution POET would be very happy to suffer. The May investor warrant at $26.25 is well above any price the shares have traded at since May 2026 and does not represent a near-term overhang at anything like current levels.

Management has quantified the upside of the warrant stack, saying at the annual meeting that up to $661 million could be raised if all warrants were exercised. The components can be reconstructed from the warrant table. The May 2026 warrants would bring in $500,000,025 at $26.25. The 36,765,940 warrants left from earlier rounds, carried at a weighted average exercise price of $3.77 at December 31, 2025, would bring in roughly $138.6 million. The 2,292,140 vested Lumilens warrants at $8.25 add $18.9 million. Those three sum to about $657.5 million, close enough to the $661 million cited that the difference sits inside the rounding on the average price. The company does not publish that breakdown, so the arithmetic above is a reconstruction from the disclosed tranches, not a company figure. What management did not say is that the $500 million half of that figure only arrives if the shares trade well above $26.25.

11 Management and governance

Suresh Venkatesan leads the company; Sandeep Kumar has been COO since May 2026, overseeing manufacturing scale. Raju Kankipati is Chief Revenue Officer and the ECOC speaker. Thomas Mika still signs the September 4 6-K as EVP and CFO; no later appointment was located in sources checked through September 20.

Bardia Pezeshki and Jean F. Rankin joined the board effective August 1 following Jean-Louis Malinge’s departure. The Q2 release says the board decided not to proceed with US redomiciliation at present. PFIC status should not be inferred from domicile or treated here as an individual tax determination.

POET · Q2 results · ECOC · official programme

Dr. Suresh Venkatesan has been chief executive since June 2015 and is also chairman. He joined POET from GlobalFoundries, where he was senior vice president of technology development and led the ramp of the 28nm node, and before that held leadership roles at Freescale Semiconductor. He holds a doctorate in electrical engineering from Purdue University and more than 25 U.S. patents. The board and the executive team have both changed materially in 2026.

• Chief financial officer transition under way. Thomas R. Mika, chief financial officer since November 2016, told the board of his intention to retire from the role during 2026 after ten years of service. The announcement was made in the same May 15, 2026 release as the $400 million financing. A search for a successor was described as commencing at that date and no appointment had been announced as of August 9, 2026. Mr. Mika continues to sign the company’s filings, including the August 3, 2026 Form 6-K.
• Chief operating officer appointed. Dr. Sandeep Kumar joined on May 11, 2026 from Silicon Labs, where he was senior vice president of worldwide operations for more than eighteen years, with earlier roles at Agere Systems, Lucent Technologies and AT&T Bell Labs. His remit is the manufacturing scale-up.
• Chief revenue officer. Raju Kankipati is quoted on the commercial announcements, including the October 2025 production order and the Lessengers partnership.
• Board renewal. Jean-Louis Malinge, lead independent director and a director since 2017, resigned effective August 1, 2026 for personal reasons, having been re-elected only five weeks earlier at the June 26 annual meeting. Dr. Bardia Pezeshki and Jean F. Rankin joined the same day. Dr. Pezeshki’s background at Avicena Tech, Kaiam and Santur is directly relevant to optical interconnect. Sohail Khan joined in July 2025 from Coherent Corp.
• Auditor. Davidson & Company LLP was reappointed at the 2026 annual meeting with 97% of votes cast.

The redomiciliation question

The plan was dropped on August 13, 2026. The second quarter results release states that, after careful consideration and with input from the company’s advisors, the board determined that at the present time it is not in the best interests of the company to move forward with redomiciling to the United States. No further explanation is given and no alternative timetable is offered. The consequence is that POET remains a foreign private issuer, keeps reporting on Form 20-F and Form 6-K rather than 10-K, 10-Q and 8-K, stays outside the proxy rules and Section 16 insider reporting, and the passive foreign investment company question stays open rather than being closed by a change of domicile.

The sequence that led there runs as follows. On April 14, 2026 POET said the board had declared its intention to move the company’s headquarters to and redomicile in the United States, so that it would cease to be a foreign corporation and could not be classified as a passive foreign investment company in future years. The chief financial officer said at the time that, to the extent redomiciling required shareholder approval, the matter would be placed on the agenda for the annual general and special meeting scheduled for June 26, 2026. The voting results published on June 30 report two matters: the election of six directors and the appointment of the auditor. No redomiciliation resolution appears in that report. The May 2026 prospectus supplement noted that POET would cease to qualify as a foreign private issuer if and when the relevant conditions occurred. Four months after the announcement of intent, the board reversed it.

12 Ownership, short interest and the retail shareholder base

POET’s register is an unusual shape. Directors and officers as a group held 128,715 shares at March 20, 2026, which on the share count of the time was under one tenth of one percent, and the 20-F table shows individual holdings in the tens of thousands: 33,892 for Malinge, 31,966 for Riley, 31,746 for Barnes, 12,500 for Mika, 11,111 for Kankipati and 7,500 for the chief executive. Finviz reports insider ownership of 0.27%. Management’s economic exposure is therefore overwhelmingly in options and restricted units, not in purchased stock.

The 13G record shows who holds size, and it is worth reading carefully because most of it is not what it first appears to be.

Finviz reports institutional ownership of 73.08%, a figure that should be read with the composition above in mind: a large part of the disclosed institutional total is market-making and dealer inventory, not long-only conviction capital, and there is no index-fund or large active-manager position on the 13G record. Outside those filings, the register is retail. POET has one of the more visible individual-investor followings among small-cap photonics names, with an active community on the AgoraCom message board and heavy daily discussion on social platforms. Retail commentary is non-professional opinion and carries no research standard: it is worth watching as a description of who owns the shares and how quickly they trade, not as evidence about the business.

Short interest is the number that dominates the trading behavior. Finviz reports 30.11% of a float of 90.48 million shares, or roughly 27.2 million shares sold short. At the reported average volume of about 30.85 million shares a day that is well under one day to cover, so this is not a classic hard-to-borrow squeeze setup; it is a very large, very liquid bearish position. It also explains the amplitude of the moves in the price table above: a 47.4% single-session fall on the Marvell cancellation, a 30.9% fall between the announcement and closing of a premium-priced financing, and a 13.45% intraday rise on August 4 on a board appointment.

The block below is a snapshot of the Stocktwits flow, with its date. These are opinions of retail traders and non-professional investors, not analyst research, and they measure attention and how one-sided positioning has become rather than anything about the business.

13 Catalysts and dates

IFOC on September 8 and CIOE on September 9–11 have passed. The September 4 6-K announced participation but does not document resulting orders. No official Q3 results date was located. The intention to provide September updates is not a promise of an order or a contractual deadline.

ECOC · official programme · ECOC · 2026 nominees · POET · CIOE · 04/09 · SEC · Q2 financial statements · POET · Q2 results

Dates in the second column of the milestone rows come from the expenditure table published inside the management discussion of August 13, 2026, which attaches a stage, a target quarter and a dollar figure to each programme. That table carries the company’s own caution that it represents management opinions and estimates and is subject to change.

14 Merlintrader bottom line

POET leaves its second quarter print as two companies that share a ticker. One is a photonics platform company with a defensible technical argument, a credible partner list and product families that have won industry awards and moved from 800G to a 1.6T and 3.2T roadmap. The other is a business that has recognised $2.66 million of revenue in three and a half years, holds $796.3 million of shareholder money, has issued 126% more shares since the start of 2025 and watched its most-cited customer relationship end in a cancellation letter.

The print itself was clean on its own terms. Revenue grew for the sixth consecutive quarter, the loss narrowed, and the cash figure that management had been quoting from a podium is now a filed number, $796,341,903, sitting inside a balance sheet with $34.3 million of total liabilities of which only $5.8 million is debt. The largest cost of the quarter was not engineering but the $6,172,500 of finance advisory fees paid to raise the money, which is a fair summary of where the company still is: the balance sheet is the achievement, the income statement is the ambition.

The evidence hierarchy is unusually clean here. Revenue on a filed income statement is fact. The Lumilens $50 million, the $5 million systems-integrator order and the new $2.4 million order announced on August 13 are signed but conditional, and the company itself says so. LITEON, Lessengers, Semtech, Sivers, NTT and QCi are development work with no order attached, two of them funded by POET, and one of them, Lessengers, is now also a company POET owns 4.99% of. The “more than $100 million in future annual revenue” from ten engagements is a management expectation. Those four tiers should not be added together, and most commentary about this company adds them together.

Three things changed on August 13 beyond the numbers. The redomiciliation to the United States, announced as a board intention in April, was dropped, which keeps POET on the foreign private issuer regime and leaves the passive foreign investment company question where it was. The company disclosed that it has become a lender, with $30 million advanced to a borrower it does not name, and a shareholder in a development partner. And management put a date on its own next move by saying further announcements will come in September, tied explicitly to confidentiality agreements, which is as close as a filing comes to saying that customer names exist and are not yet public.

What has not changed is the shape of the question. POET no longer has a funding problem and, with $796 million against a $49 million annual operating burn, will not have one for a long time. It has a delivery problem. The company says it will begin shipping substantial numbers of production units for qualification in the remaining quarters of 2026; the third quarter report, due by November 14, is the first document in which that claim becomes checkable against a revenue line, a deferred balance and a capital expenditure figure.

For broader catalyst tracking across the space, defense and AI complex, the Merlintrader Free Catalyst Calendar lists the dated events for the sector.

15 Related Research On Merlintrader

• Why AI Needs Optics: the optical interconnect stack explained — the framework behind the technology section above, from pluggables to co-packaged optics.
• Three different ways to play the AI photonics race — how $POET compares with larger listed optical component suppliers.
• The Marvell cancellation of the Celestial AI orders — the April 2026 event covered in detail at the time.
• LightPath Technologies ($LPTH) Stock Hub — another small-cap optics manufacturer with a defense and infrared angle.
• Dilution, ATM offerings, PIPE deals and reverse splits: a practical guide — background for the capital structure section.
• Space, Defense & AI Stock Hubs 2026 — the full index of company hubs in this sector.
• Weekly Market Pulse — the week ahead across catalysts and earnings.

Sources and review date

September 20, 2026 · SEC, POET investor relations, ECOC. Finviz supplies secondary market data.

SEC · Q2 financial statements · SEC · MD&A · 13/08 · POET · Q2 results · SEC · Group One · 08/09 · POET · CIOE · 04/09 · POET · Lumilens · 14/05 · ECOC · official programme · ECOC · 2026 nominees · POET · News & Media · Finviz · 20/09